Abbott To Pay $385 Million To Settle Baby Formula Safety Allegations

Search and coverage interest is spiking around reports that Abbott may pay $385 million to settle baby formula safety allegations, though the specific trigger for the surge has not been confirmed. The figure has not been verified against any official announcement, court filing, or company statement, and it remains unclear whether a settlement has actually been reached.

The topic drawing attention is Abbott’s potential $385 million payment to resolve allegations tied to its baby formula products. The reports point to safety allegations, but the details — which allegations are covered, which jurisdiction or forum is involved, and whether the figure represents a final agreement or a proposal — have not been confirmed.

What is long-established is that Abbott faced significant scrutiny over its infant formula operations following the February 2022 recall at its Sturgis, Michigan plant. The shutdown of that facility contributed to a nationwide formula shortage, prompted an FDA investigation, and led to a series of lawsuits from families and consumers. Any settlement figure would be read against that history, but the current reports remain unverified.

Why These Reports Are Drawing Attention

The reports matter because a $385 million settlement would rank among the larger resolutions in the baby formula safety saga. Abbott has already faced civil and criminal scrutiny over the Sturgis plant, including a 2024 agreement with the Department of Justice related to the facility’s operations.

For readers, the significance is twofold. First, it signals that the legal fallout from the 2022 recall continues to unfold, with financial consequences that could reach hundreds of millions of dollars. Second, it underscores the ongoing public-health stakes: the recall and subsequent shortage affected millions of families, and any settlement would be a formal acknowledgment of harm alleged by plaintiffs.

The 2022 Recall and Its Aftermath

The backdrop is the February 2022 recall of Abbott’s Similac, Alimentum, and EleCare formulas produced at the Sturgis, Michigan plant. The FDA linked the facility to bacterial contamination reports, including Cronobacter sakazakii infections in infants. The plant’s closure triggered a severe nationwide formula shortage, forcing the FDA and the White House to take emergency steps to import formula from overseas.

Abbott has maintained that no formula from the plant was confirmed to have caused the reported infections, but the company faced dozens of civil lawsuits from families alleging injuries and deaths. In 2024, Abbott agreed to a $95 million criminal and civil settlement with the Department of Justice over the plant’s operations, while continuing to contest individual injury claims. The reported $385 million figure would represent a separate or additional resolution, but that remains unconfirmed.

What Is Still Unverified

The core uncertainty is whether Abbott has actually agreed to pay $385 million. No official announcement from Abbott, no court filing, and no regulatory statement has been confirmed. The reports could stem from a leaked negotiation, a speculative analyst note, or a misreading of an existing settlement figure.

It is also unclear which allegations the reported figure would cover — whether it addresses the individual injury lawsuits, the DOJ-related matters, or a new class action. The timing of any formal announcement, if one exists, is unknown. Readers should treat the $385 million figure as an unverified report until a primary source confirms it.

Watching for Official Confirmation

The next development to watch is whether Abbott, plaintiffs’ counsel, or a court issues a formal statement confirming or denying the reported settlement. If a deal has been reached, it would likely appear in a court filing or a company press release. If the reports are premature or inaccurate, Abbott may issue a denial.

Until then, the $385 million figure should be treated as a reported number, not a confirmed fact. Investors, families affected by the recall, and industry observers will be watching for official word on the scope and terms of any agreement.

Key Questions

Has Abbott confirmed it will pay $385 million?

No. As of this writing, no official confirmation from Abbott, a court, or a regulator has been verified. The figure comes from unconfirmed reports and should be treated as a claim until a primary source confirms it.

What baby formula safety allegations are involved?

The reports do not specify which allegations the $385 million would cover. The broader context involves lawsuits tied to Abbott’s 2022 recall of Similac, Alimentum, and EleCare formula produced at its Sturgis, Michigan plant, which was linked to bacterial contamination reports.

Has Abbott settled similar cases before?

Yes. In 2024, Abbott reached a $95 million agreement with the Department of Justice related to the Sturgis plant’s operations. The company has continued to contest individual injury claims, and the reported $385 million figure would be separate from or additional to that earlier agreement.

Why does the $385 million figure matter?

If confirmed, it would be one of the largest financial resolutions in the baby formula safety saga, signaling that the legal and financial fallout from the 2022 recall is still growing. It would also represent a formal acknowledgment of harm alleged by plaintiffs.

What should readers do with this information?

Treat it as an unconfirmed report, not a settled fact. Wait for official confirmation from Abbott, plaintiffs’ counsel, or a court before treating the settlement as real. The situation is developing and details could change.

Source: rss